NASDAQ:MESO

Mesoblast Stock News

Healthcare > Biotechnology

Buy MESO

*Your capital is at risk

$14.17

-0.380 (-2.61%)

At Close: Jul 31, 2026

Successful Commercial Launch of Ryoncil®

08:38pm, Thursday, 17'th Jul 2025

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

08:46am, Tuesday, 01'st Jul 2025

On Monday, Mesoblast Ltd. MESO announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) f

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

08:36pm, Monday, 30'th Jun 2025

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

09:24pm, Wednesday, 11'th Jun 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum w

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

10:57pm, Wednesday, 14'th May 2025

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

02:44am, Monday, 05'th May 2025

MESO's Off-the-shelf MSC/MPC platform treats severe inflammatory diseases without donor–recipient matching. This alleviates the typical need for immunosuppression. The FDA recently approved Ryoncil,

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

08:53pm, Tuesday, 29'th Apr 2025

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

07:44pm, Monday, 28'th Apr 2025

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Coble

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

09:20pm, Wednesday, 16'th Apr 2025

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

06:58pm, Thursday, 03'rd Apr 2025

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its p

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

07:15pm, Wednesday, 02'nd Apr 2025

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet w

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by